Cord blood (CB) is becoming an important source for allo-hematopoietic SCT (HSCT), 1 yet engraftment failure remains a significant problem. 2 Some clinicians have reported successful engraftment of CB with reducedintensity CB transplantation 3 for treatment of graft failure. However, an optimal conditioning regimen has yet to be established.
We report two cases of patients with acute leukemia who suffered from graft failure and sepsis but achieved engraftment of CB after a conditioning regimen of fludarabine 30 mg/m 2 i.v., CY 2 g/m 2 i.v. and TBI 2 Gy administered one day before the transplantation (one-day regimen), as modified from a regimen developed by Goggins et al.
4
Patient 1 is a 42 year-old man with acute myelogenous leukemia diagnosed in February 2006. On personal request, he received CB transplantation (CBT) during his first CR in July 2006, using a female CB graft after a conditioning regimen of CY 60 mg/kg i.v. for 2 consecutive days and TBI 2 Gy twice daily for 3 consecutive days. Subsequent to a relapse 4 months later, he underwent a second CBT in January 2007. BM analysis 7 days before the initiation of conditioning showed that 28.6% of nucleated cells were leukemic blasts. The preparative conditioning regimen consisted of fludarabine 30 mg/m 2 daily i.v. for 6 consecutive days (total 180 mg/m 2 ) and BU 3.2 mg/kg daily i.v. for 4 consecutive days (total 12.8 mg/kg). We used a male CB graft that was 2-loci HLA-mismatched and contained 1.87 Â 10 7 nucleated cells/kg (0.41 Â 10 5 CD34 þ cells/kg). Owing to prolonged neutropenia, the patient developed pharyngitis followed by sepsis. He tested positive for blood endotoxin, and pharyngeal culture showed the presence of Pseudomonas aeruginosa. BM examination on day 39 after the second CBT showed increased hemophagocytic macrophages with 0.2% blasts, indicating a hemophagocytic syndrome-like condition. After administration of 1 mg/kg prednisolone, neutropenia persisted with 100% lymphocytes detected by peripheral white blood cell analysis. FISH analysis of peripheral blood, even after day 21 of the second CB graft, showed that 99.6% of cells were of female origin. From these findings, we diagnosed the patient with graft failure.
We then carried out a third CBT using a 2-loci HLAmismatched female CB graft containing 2.1 Â 10 7 nucleated cells/kg (0.86 Â 10 5 CD34 þ cells/kg) on day 48 after the second CBT. As the patient was septic and suffering from subclinical veno-occlusive disease, we decided on the one-day conditioning regimen. On day 12, the patient developed mucositis and multidrug-resistant P. aeruginosa bacteremia. However, his high fever began to abate on day 20 after the third CBT and his neutrophil count surpassed 0.5 Â 10 9 /l on day 24. DNA chimerism analysis on day 76 showed that whole blood cells and CD3 þ lymphocytes were completely of the third donor type. /l and the percentage of neutrophils was only 1% on day 21. Chimerism analysis of peripheral blood on day 24 showed that whole blood cells and CD3 þ cells were completely of the recipient type. From these findings, we diagnosed the patient as having graft failure. We carried out a second CBT, using a 1-locus HLA-mismatched female CB graft containing 2.23 Â 10 7 nucleated cells/kg (0.34 Â 10 5 CD34 þ cells/kg) on day 34 after the first CBT. We decided to use the one-day regimen as the patient was septic. The neutrophil count surpassed 0.5 Â 10 9 /l on day 26. Chimerism analysis using peripheral blood DNA on day 22 showed that whole blood cells and CD3 þ lymphocytes were completely of the second CB type. FISH analysis of BM on day 48 showed that 99.6% of cells were of female origin derived from the second CB given that chimerism analyses confirmed that peripheral blood on day 24 after the first CBT was of recipient origin and that on day 22 after the second CBT was of donor origin. Although leukemia relapsed 7 months after the third transplantation, the patient is still alive 10 months after transplantation.
In addition to CB as a stem cell source, other reasons have been reported as risk factors for engraftment failure. These include low count of infused nucleated cells, non-TBI regimen, 5 severe infection and hemophagocytic syndrome. In the case of patient 1, the low CD34 þ cell count, 6 non-TBI regimen and hemophagocytic syndrome-like condition may have caused graft failure. In the case of patient 2, bacteremia may have been associated with poor engraftment. Furthermore, factors other than conditioning regimens may have favorably affected CB engraftments. These include higher doses of nucleated cells in the third CBT in patient 1 and second CBT in patient 2 than those in earlier CBTs, and better HLA matching in the second CBT in patient 2 than that in the first CBT.
A standard regimen to rescue patients suffering from primary graft failure after transplantation has yet to be established. Goggins et al. used a one-day regimen consisting of fludarabine, alemtuzumab, and CY to treat five leukemia patients with allogeneic PBSC transplantation from related donors and observed engraftment in three patients. 4 The original regimen contained alemtuzumab in order to increase immunosuppression. We did not include alemtuzumab or anti-thymocyte globulin in the conditioning regimen for our patients in light of their sepsis. A shortened pre-conditioning time of one day may help patients survive a neutropenic period from the start of pre-conditioning to neutrophil engraftment. When salvage CBT is considered for patients suffering graft failure and severe infections such as sepsis, this regimen may be a promising choice. Department of Hematology, Nagano Red Cross Hospital, Nagano, Japan and
